[1] SAN R GM,POZAS J,MOLINA-CERRILLO J,et al.Current and future role of tyrosine kinases inhibition in thyroid cancer:From biology to therapy［J］.Int J Mol Sci,2020,21(14):4951.
[2] MITCHELL AL,GANDHI A,SCOTT-COOMBES D,et al.Management of thyroid cancer:United Kingdom National Multidisciplinary Guidelines［J］.J Laryngol Otol,2016,130(S2):S150-S160.
[3] KIM DH,JUNG JH,SON SH,et al.Difference of clinical and radiological characteristics according to radioiodine avidity in pulmonary metastases of differentiated thyroid cancer［J］.Nucl Med Mol Imaging,2014,48(1):55-62.
[4] 张鑫,林岩松.非远处转移性分化型甲状腺癌~(131)I治疗进展-2019年《ESMO临床实践指南：甲状腺癌的诊断、治疗和随访》解读［J］.中华核医学与分子影像杂志,2020,40(06):343-350.
ZHANG X,LIN YS.New progress in radioiodine therapy of differentiated thyroid cancer without distant metastases:the interpretation of thyroid cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow-up［J］.Chinese Journal of Nuclear Medicine and Molecular Imaging,2020,40(06):343-350.
[5] SPAAS M,DECALLONNE B,LAENEN A,et al.Prognostic value of stimulated thyroglobulin levels at the time of radioiodine administration in differentiated thyroid cancer［J］.Eur Thyroid J,2018,7(4):211-217.
[6] HAUGEN BR.2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:What is new and what has changed［J］.Cancer,2017,123(3):372-381.
[7] HAUGEN BR,ALEXANDER EK,BIBLE KC,et al.2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer［J］.Thyroid,2016,26(1):1-133.
[8] DURANTE C,HADDY N,BAUDIN E,et al.Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma:benefits and limits of radioiodine therapy［J］.J Clin Endocrinol Metab,2006,91(8):2892-2899.
[9] OKAMOTO S,SHIGA T,UCHIYAMA Y,et al.Lung uptake on 131I therapy and short-term outcome in patients with lung metastasis from differentiated thyroid cancer［J］.Ann Nucl Med,2014,28(2):81-87.
[10] QUTBI M,SHAFEIE B,AMOUI M,et al.Evaluation of prognostic factors associated with differentiated thyroid carcinoma with pulmonary metastasis［J］.Clin Nucl Med,2016,41(12):917-921.
[11] 中国临床肿瘤学会指南工作委员会甲状腺癌专家委员会.中国临床肿瘤学会(CSCO)持续/复发及转移性分化型甲状腺癌诊疗指南-2019［J］.肿瘤预防与治疗,2019,32(12):1051-1080.
Expert Panel on Thyroid Cancer,Guidelines Working Committee of Chinese Society of Clinical Oncology,Guidelines of Chinese Society of Clinical Oncology(CSCO):Persistent/recurrent and metastatic differentiated thyroid cancer-2019［J］.J Cancer Control Treat,2019,12(32):1051-1080.
[12] CAMPENNI A,AMATO E,LAUDICELLA R,et al.Recombinant human thyrotropin(rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients:differences in abdominal absorbed dose［J］.Endocrine,2019,65(1):132-137.
[13] LAWAL IO,NYAKALE NE,HARRY LM,et al.Higher preablative serum thyroid-stimulating hormone level predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma［J］.Nucl Med Commun,2017,38(3):222-227.
[14] ROBBINS RJ,TUTTLE RM,SONENBERG M,et al.Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin［J］.Thyroid,2001,11(9):865-869.
[15] HA J,KIM MH,JO K,et al.Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict structural incomplete response to treatment in patients with differentiated thyroid cancer［J］.Medicine(Baltimore),2017,96(29):e7512.
[16]］ GIOVANELLA L,PICCARDO A.A "new/old method" for TSH stimulation:could a third way to prepare DTC patients for (131)I remnant ablation possibly exist［J］.Eur J Nucl Med Mol Imaging,2016,43(2):221-223.
[17] PICCARDO A,PUNTONI M,FERRARAZZO G,et al.Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients［J］.Eur J Nucl Med Mol Imaging,2018,45(7):1218-1223.
[18] GIOVANELLA L,DUNTAS LH.Management of endocrine disease:The role of rhTSH in the management of differentiated thyroid cancer:pros and cons［J］.Eur J Endocrinol,2019,181(4):R133-R145.
[19] CAMPENNI A,GIOVANELLA L,PIGNATA SA,et al.Thyroid remnant ablation in differentiated thyroid cancer:searching for the most effective radioiodine activity and stimulation strategy in a real-life scenario［J］.Nucl Med Commun,2015,36(11):1100-1106.
[20] DINAN MA,LI Y,REED SD,et al.Initial adoption of recombinant human thyroid-stimulating hormone following thyroidectomy in the medicare thyroid cancer patient population［J］.Endocr Pract,2019,25(1):31-42.
[21] KOWALSKA A,PALYGA I,GASIOR-PERCZAK D,et al.The cut-off level of recombinant human TSH-stimulated thyroglobulin in the follow-up of patients with differentiated thyroid cancer［J］.PLoS One,2015,10(7):e133852.
[22] MUTSUDDY P,JEON S,YOO SW,et al.Optimization of serum thyroglobulin measured at different time points for prognostic evaluation in differentiated thyroid carcinoma patients［J］.Medicine(Baltimore),2020,99(14):e19652.
[23] TORRES MS,RAMIREZ L,SIMKIN PH,et al.Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects［J］.J Clin Endocrinol Metab,2001,86(4):1660-1664.
[24] VALLE LA,GORODESKI BR,PORTER K,et al.In thyroidectomized patients with thyroid cancer,a serum thyrotropin of 30 mIU/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin［J］.Thyroid,2013,23(2):185-193.
[25] ZHAO T,LIANG J,GUO Z,et al.In Patients with low-to intermediate-risk thyroid cancer,a preablative thyrotropin level of 30 mIU/mL is not adequate to achieve better response to 131I therapy［J］.Clin Nucl Med,2016,41(6):454-458.
[26] RAHMOUN MN,BENDAHMANE I.Anti-thyroglobulin antibodies in differentiated thyroid carcinoma patients:Study of the clinical and biological parameters［J］.Ann Endocrinol(Paris),2014,75(1):15-18.
[27] RINGEL MD,NABHAN F.Approach to follow-up of the patient with differentiated thyroid cancer and positive anti-thyroglobulin antibodies［J］.J Clin Endocrinol Metab,2013,98(8):3104-3110.
[28] SPENCER C,LOPRESTI J,FATEMI S.How sensitive(second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer,in the absence or presence of thyroglobulin autoantibodies［J］.Curr Opin Endocrinol Diabetes Obes,2014,21(5):394-404.
[29] 赵腾,梁军,林岩松.(131)I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义［J］.国际放射医学核医学杂志,2015,39(01):61-66.
ZHAO T,LIANG J,LIN YS,et al.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma［J］.Int J Radiat Med Nucl Med,2015,39(01):61-66.
[30] BALOCH Z,CARAYON P,CONTE-DEVOLX B,et al.Laboratory medicine practice guidelines.Laboratory support for the diagnosis and monitoring of thyroid disease［J］.Thyroid,2003,13(1):3-126.
[31] LI S,REN C,GONG Y,et al.The role of thyroglobulin in preoperative and postoperative evaluation of ptients with differentiated thyroid cancer［J］.Front Endocrinol(Lausanne),2022,13:872527.
[32] 赵连春,刘光霞,陈芳,等.血清甲状腺球蛋白在分化型甲状腺癌术后转移的诊断预测效能分析［J］.热带医学杂志,2020,20(12):1569-1572.
ZHAO LC,LIU GX,CHEN F,et al.Diagnostic and predictive efficacy of serum ps-Tg in postoperative metastasis of DTC［J］.J Trop Med,,2020,20(12):1569-1572.
[33] COUTO JS,ALMEIDA M,TRINDADE V,et al.A cutoff thyroglobulin value suggestive of distant metastases in differentiated thyroid cancer patients［J］.Braz J Med Biol Res,2020,53(11):e9781.
[34] 丁颖,杨辉,李文亮,等.分化型甲状腺癌术后首次血清刺激性Tg水平对远处转移的预测价值［J］.国际放射医学核医学杂志,2019,43(4):6.
DING Y,YANG H,LI WL,et al.Predictive value of postoperative initial stimulated thyroglobulin level on distant metastasis of differentiated thyroid carcinoma［J］.Int J Radiat Med Nucl Med,2019,43(4):6.
[35] REN L,ZHANG C,SHEN Y,et al.The value of stimulated thyroglobulin before the first radioactive iodine treatment in metastasis for differentiated thyroid carcinoma［J］.Clin Lab,2021,67(6).DOI:10.7754/Clin.Lab.2020.201032.PMID:34107643.
[36] 唐梁思成,李智勇,朱辉,等.分化型甲状腺癌全切术患者首次(131)I治疗前血清ps-Tg对单纯肺转移的预测价值［J］.山东医药,2021,61(14):51-53.
TANG LSC,LI ZY,ZHU H,et al.Predictive value of serum ps-Tg in patients with differentiated thyroid carcinoma before the first 131I treatment for pure lung metastasis［J］.Shandong Medical Journal,2021,61(14):51-53.
[37] 王芳,王越,刁宏翠,等.分化型甲状腺癌术后再次~(131)I治疗前sTg与sTg/sup-Tg对淋巴结转移的预测价值［J］.现代肿瘤医学,2020,28(14):2417-2421.
WANG F,WANG Y,DIAO HC,et al.The predictive value of sTg and sTg/sup -Tg on lymph node metastasis of differentiated thyroid cancer before the second 131I ablation［J］.Modern Oncology,2020,28(14):2417-2421.
[38] GRIGSBY PW,GAL-OR A,MICHALSKI JM,et al.Childhood and adolescent thyroid carcinoma［J］.Cancer,2002,95(4):724-729.
[39] LIU L,HUANG F,LIU B,et al.Detection of distant metastasis at the time of ablation in children with differentiated thyroid cancer:the value of pre-ablation stimulated thyroglobulin［J］.J Pediatr Endocrinol Metab,2018,31(7):751-756.
[40] LIVHITS MJ,PASTERNAK JD,XIONG M,et al.Pre-ablation thyroglobulin and thyroglobulin to thyroid-stimulating hormone ratio may be associated with pulmonary metastases in children with differentiated thyroid cancer［J］.Endocr Pract,2016,22(11):1259-1266.
[41] 孙迪,赵腾,张迎强,等.儿童及青少年分化型甲状腺癌患者术后131I治疗前刺激性Tg对远处转移的预测价值［J］.中华核医学与分子影像杂志,2021,41(6):6
SUN D,ZHAO T,ZHANG YQ,et al.Predictive value of preablative stimulated thyroglobulinindetection of distant metastasis in children and adolescents with differentiated thyroid carcinoma［J］.Chin J Nucl Med Mol Imaging,2021,41(6):6.
[42] WEBB RC,HOWARD RS,STOJADINOVIC A,et al.The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer:a meta-analysis involving 3947 patients［J］.J Clin Endocrinol Metab,2012,97(8):2754-2763.
[43] LIN Y,LI T,LIANG J,et al.Predictive value of preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio in differentiated thyroid cancer［J］.Clin Nucl Med,2011,36(12):1102-1105.
[44] TREVIZAM PG,TAGLIARINI JV,CASTILHO EC,et al.Thyroglobulin levels and thyroglobulin/thyrotropin ratio could predict the success of the ablative/therapeutic (131)I in the differentiated thyroid cancers［J］.Endocr Res,2017,42(1):42-48.
[45] JU Y,WANG L,CHENG F,et al.Comparing the efficacy of thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio models in predicting a successful response to radioactive iodine therapy［J］.BMC Endocr Disord,2023,23(1):19.
[46] DEMIR F,SIMSEK FS,ANSAL BT.The role of pre-ablative stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio for predicting metastasis in thyroid cancer［J］.Mol Imaging Radionucl Ther,2019,28(1):21-26.
[47] MOON JH,CHOI JY,JEONG WJ,et al.Recombinant human thyrotropin-stimulated thyroglobulin level at the time of radioactive iodine ablation is an independent prognostic marker of differentiated thyroid carcinoma in the setting of prophylactic central neck dissection［J］.Clin Endocrinol(Oxf),2016,85(3):459-465.
[48] ZHAO T,LIANG J,LI T,et al.Value of serial preablative thyroglobulin measurements:can we address the impact of thyroid remnants［J］.Nucl Med Commun,2016,37(6):632-639.
[49] ZHAO T,LIANG J,LI T,et al.Serial stimulated thyroglobulin measurements are more specific for detecting distant metastatic differentiated thyroid cancer before radioiodine therapy［J］.Chin J Cancer Res,2017,29(3):213-222.
[50] 赵腾,李田军,丛慧,等.动态监测~(131)I治疗前刺激性Tg在DTC远处转移诊治中的增益效应［J］.肿瘤学杂志,2015,21(06):459-464.
ZHAO T,LI TJ,CONG H,et al.The incremental effect of dynamically tracing pre-ablation stimulated thyroglobulin in the diagnosis and treatment for distant metastasis in differentiated thyroid cancer［J］.Journal of Chinese Oncology,2015,21(06):459-464.
[51] 陈鹏,宋长祥,陆武,等.首次~(131)I治疗前监测甲状腺球蛋白预测分化型甲状腺癌转移的临床价值［J］.中华内分泌代谢杂志,2018,34(02):102-105.
CHEN P,SONG CX,LU W,et al.Clinical significance of tracing thyroglobulin in predicting metastasis of post-operative patients with differentiated thyroid carcinoma before its first pre-ablation with 131I［J］.Chinese Journal of Endocrinology and Metabolism,2018,34(02):102-105.
[52] KOHNO Y,TARUTANI O,SAKATA S,et al.Monoclonal antibodies to thyroglobulin elucidate differences in protein structure of thyroglobulin in healthy individuals and those with papillary adenocarcinoma［J］.J Clin Endocrinol Metab,1985,61(2):343-350.
[53] 李成乾,王国强,王叙馥,等.首次~(131)I治疗前刺激性Tg对分化型甲状腺癌转移的预测价值［J］.中华核医学与分子影像杂志,2019,39(07):395-399.
LI CQ,WANG GQ,WANG XF,et al.Predictive value of stimulated thyroglobulin for metastases from differentiated thyroid carcinoma before the first 131I treatment［J］.Chinese Journal of Nuclear Medicine and Molecular Imaging,2019,39(07):395-399.
[54] 武鸿文,赵力威,段云,等.甲状腺球蛋白与分化型甲状腺癌转移灶的关系分析［J］.实用癌症杂志,2016,31(02):221-223.
WU HW,ZHAO LW,DUAN Y,et al.Relationship between thyroglobulin and metastases of differentiated thyroid carcinoma［J］.The Practical Journal of Cancer,2016,31(02):221-223.
[55] 刘安民,王永梅,李玥.分析甲状腺球蛋白(TG)与分化型甲状腺癌转移灶的相关性及TG的诊断意义［J］.当代医学,2015,21(36):43-44.
LIU AM,WANG YM,LI Y,et al.Analysis of the correlation between thyroid globulin(TG) and differentiated thyroid cancer metastasis and the diagnostic significance of TG［J］.Contemporary Medicine,2015,21(36):43-44.